1] Institute of Oncologic Pathology, The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, Guangdong, China [2] Department of Clinical Laboratory, the Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Department of Clinical Laboratory, the Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Am J Gastroenterol. 2014 Jan;109(1):36-45. doi: 10.1038/ajg.2013.384. Epub 2013 Dec 3.
Esophageal squamous cell carcinoma (ESCC) is one of the most frequent causes of cancer death worldwide and effective diagnosis is needed. We assessed the diagnostic potential of an autoantibody panel that may benefit early diagnosis.
We analyzed data for patients with ESCC and normal controls in a test cohort and a validation cohort. Autoantibody levels were measured against a panel of six tumor-associated antigens (p53, NY-ESO-1, matrix metalloproteinase-7 (MMP-7), heat shock protein 70 (Hsp70), peroxiredoxin VI (Prx VI), and BMI1 polycomb ring finger oncogene (Bmi-1)) by enzyme-linked immunosorbent assay.
We assessed serum autoantibodies in 513 participants: 388 with ESCC and 125 normal controls. The validation cohort comprised 371 participants: 237 with ESCC, and 134 normal controls. Autoantibodies to at least 1 of 6 antigens demonstrated a sensitivity/specificity of 57% (95% confidence interval (CI): 52-62%)/95% (95% CI: 89-98%) and 51% (95% CI: 45-57%)/96% (95% CI: 91-99%) in the test and validation cohorts, respectively. Measurement of the autoantibody panel could differentiate early-stage ESCC patients from normal controls (sensitivity 45% (95% CI: 32-59%) and specificity 95% (95% CI: 89-98%) in the test cohort; 46% (95% CI: 35-58%) and 96% (95% CI: 91-99%) in the validation cohort). In either cohort, no significant differences were seen when patients were subdivided by age, gender, smoking status, size of tumor, site of tumor, depth of tumor invasion, histological grade, lymph node status, TNM stage, or early-stage and late-stage groups.
Measurement of an autoantibody response to multiple tumor-associated antigens in an optimized panel assay, to help discriminate early-stage ESCC patients from normal controls, may aid in early detection of ESCC.
食管鳞状细胞癌（ESCC）是全球癌症死亡的最常见原因之一，需要有效的诊断。我们评估了一种自身抗体谱的诊断潜力，该抗体谱可能有助于早期诊断。
我们在一个测试队列和一个验证队列中分析了 ESCC 患者和正常对照者的数据。通过酶联免疫吸附试验，用一组 6 种肿瘤相关抗原（p53、NY-ESO-1、基质金属蛋白酶-7（MMP-7）、热休克蛋白 70（Hsp70）、过氧化物还原酶 VI（Prx VI）和 BMI1 多梳环指 oncogene（Bmi-1））对血清自身抗体进行了检测。
我们评估了 513 名参与者的血清自身抗体：388 名 ESCC 患者和 125 名正常对照者。验证队列包括 371 名参与者：237 名 ESCC 患者和 134 名正常对照者。对至少 1 种 6 种抗原的自身抗体的敏感性/特异性分别为 57%（95%置信区间（CI）：52-62%）/95%（95%CI：89-98%）和 51%（95%CI：45-57%）/96%（95%CI：91-99%）在测试和验证队列中。自身抗体谱的测量可以将早期 ESCC 患者与正常对照组区分开来（在测试队列中，敏感性为 45%（95%CI：32-59%）和特异性为 95%（95%CI：89-98%）；在验证队列中，敏感性为 46%（95%CI：35-58%）和特异性为 96%（95%CI：91-99%））。在两个队列中，当患者按年龄、性别、吸烟状况、肿瘤大小、肿瘤部位、肿瘤浸润深度、组织学分级、淋巴结状态、TNM 分期或早期和晚期分组时，均未见显著差异。
在优化的面板检测中测量针对多种肿瘤相关抗原的自身抗体反应，有助于将早期 ESCC 患者与正常对照者区分开来，可能有助于早期发现 ESCC。
